Crossmark

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Crossref DOI link: https://doi.org/10.1186/s12885-021-07826-4

Published Online: 2021-02-06

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tran, Khanh B.

Kolekar, Sharada

Jabed, Anower

Jaynes, Patrick

Shih, Jen-Hsing

Wang, Qian

Flanagan, Jack U.

Rewcastle, Gordon W.

Baguley, Bruce C.

Shepherd, Peter R.
Funding

Funding for this research was provided by:

Cancer Society of New Zealand

Health Research Council of New Zealand

Maurice Wilkins Centre for Molecular Biodiscovery
License Information

Text and Data Mining valid from 2021-02-06

Version of Record valid from 2021-02-06
More Information

Article History

Received: 10 September 2020

Accepted: 20 January 2021

First Online: 6 February 2021

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below